LearnGlossaryMarketStocksSuperinvestorsSign in

DFTX

Definium Therapeutics, Inc.

Healthcare · $5.0B market cap

Verdict

We can't put a fair value on DFTX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-17.2% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-42.5%✗

Follow DFTX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 2, 2026: no open-market purchases, 1 sale worth $722K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Barrow Robert

Chief Executive Officer · 2026-09-03

Sold

$722K

Other filings

Barrow Robert

Chief Executive Officer · 2026-09-02

Award

40,000 shares

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works